Peptic ulcer disease continues to be a source of significant morbidity and mortality
worldwide. Approximately two-thirds of patients found to have peptic ulcer disease are …

Background The introduction of proton pump inhibitors (PPIs) into clinical practice has
revolutionized the management of acid-related diseases. Studies in primary care and …

Advances in bioinspired design principles and nanomaterials have led to tremendous
progress in autonomously moving synthetic nano/micromotors with diverse functionalities in …

Gastroesophageal reflux disease (GERD) is arguably the most common disease
encountered by the gastroenterologist. It is equally likely that the primary care providers will …

Vitamin B12 (cobalamin, Cbl, B12) is an indispensable water-soluble micronutrient that
serves as a coenzyme for cytosolic methionine synthase (MS) and mitochondrial …

RH: consultant to Takeda R&D Europe and have been a speaker for Takeda symposia also
a consultant to Novartis and Insys. DA: consulted with Pfizer on PPI therapy, after completion …

Background Proton pump inhibitors (PPI s) have a well‐established safety profile. However,
concerns have been raised about a potential relationship between PPI‐induced …

Proton-pump inhibitors (PPIs) remain the leading evidence-based therapy for upper
gastrointestinal disorders, including gastroesophageal reflux disease, dyspepsia, and peptic …

The highly acidic gastric environment creates a physiological barrier for using therapeutic
drugs in the stomach. While proton pump inhibitors have been widely used for blocking acid …

Background Acid inhibitory effects of proton pump inhibitors (PPI s) are influenced by CYP
2C19 genotype. In contrast, the potent acid inhibition of vonoprazan is not influenced by …